ENTITY
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals (GNP IN)

169
Analysis
Health Care • India
Glenmark Pharmaceuticals Ltd., is a pharmaceutical company. The Company develops generic drugs for inflammation, metabolic disorders, and pain.
more
bearish•MSCI World Index
•15 Nov 2018 21:39

Global Markets Outlook: Maintain Defensive Posture

Our outlook for global equity markets remains cautious and we expect additional weakness and consolidation, notwithstanding shorter-term...

Logo
693 Views
Share
•05 Nov 2018 22:59

EM Strategy: Brazil Breaking Out, EM Energy Remains Attractive

While the MSCI EM index remains in a well-defined downtrend, and we continue to recommend selectivity, we highlight several investable themes and...

Logo
632 Views
Share
•02 Nov 2018 00:00

Asia HY Monthly - Corporate Governance In Chinese Companies - Lucror Analytics

In this month’s “In-Focus” section, we discuss Corporate Governance in Chinese Companies. Specifically, we highlight: [1] the nascent development...

Logo
204 Views
Share
•12 Oct 2018 09:26

Glenmark Pharmaceuticals: Attempt Out of Generic

We initiate our coverage on Glenmark Pharmaceuticals (GNP IN) (“Glenmark”)’s GNPIN 4.5% 8/21s (BB-/BB by S&P and Fitch, respectively) with a...

Logo
540 Views
Share
•26 Aug 2018 23:31

EM Strategy: Remain Overweight India

In this report we provide a synopsis of EM markets. We also scour the EM universe for attractive and actionable opportunities, highlighting...

Logo
532 Views
Share
x